Table 2.

NMA Fixed effects results, SMDs converted to log odds ratios for slowing the decline in FVC

			Log odds ratios			Odds ratios
Comparator (vs. placebo)	N studies	Total N participants	Mean	95% CrI		Mean	95% CrI
Azathioprine	1	19	0.44	-0.30	1.19	1.56	0.74	3.29
Nintedanib	1	170	-0.97	-1.52	-0.41	0.38	0.22	0.66
NAC triple therapy	2	294	-0.06	-0.60	0.48	0.94	0.55	1.62
Inhaled NAC	1	76	-0.42	-1.24	0.40	0.66	0.29	1.49
Pirfenidone	4	1006	-0.39	-0.62	-0.16	0.68	0.54	0.85
Sildenafil	1	180	-0.12	-0.65	0.41	0.89	0.52	1.51
Head-to-head comparison
Nintedanib vs. Pirfenidone	-0.58			-1.18	0.03	0.56	0.31	1.03